1. Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype

   • Antonio Marchesoni

   Commentary Open access 01 June 2018 Pages: 311 - 316

2. Chikungunya Infection: A Re-emerging Epidemic

   • Binoy J. Paul
   • Shajit Sadanand

   Review Open access 25 July 2018 Pages: 317 - 326

   

3. Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK

   • Sara Gale
   • Jessica C. Wilson
   • Khaled Sarsour

   Original Research Open access 11 May 2018 Pages: 327 - 340

   

4. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses

   • Vibeke Strand
   • Arthur Kavanaugh
   • Josef S. Smolen

   Original Research Open access 14 May 2018 Pages: 341 - 353

   

5. Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

   • David M. Kern
   • Lawrence Chang
   • Andre B. Araujo

   Original Research Open access 30 May 2018 Pages: 355 - 369

   

6. Patients with Rheumatic Diseases do not have an Increased Risk of MRSA Carrier Status

   • Judith Krämer
   • Konstantinos Triantafyllias
   • Andreas Schwarting

   Original Research Open access 02 June 2018 Pages: 371 - 381

7. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

   • Stephen Hall
   • Peter Nash
   • Krishan Thirunavukkarasu

   Original Research Open access 11 June 2018 Pages: 383 - 401

   

8. Similar Pharmacokinetics of the Adalimumab (Humira^®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE^®-AI and VOLTAIRE^®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials

   • Steven Ramael
   • Benjamin Van Hoorick
   • Girish Jayadeva

   Original Research Open access 29 June 2018 Pages: 403 - 421

   

9. Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study

   • Kurt de Vlam
   • Joseph F. Merola
   • Wolf-Henning Boehncke

   Original Research Open access 06 July 2018 Pages: 423 - 436

   

10. The Prevalence of Non-radiographic Axial Spondyloarthritis Among Patients with Inflammatory Back Pain from Northwest and South Africa: Data from a Noninterventional, Cross-Sectional Study

    • Khalid Shirazy
    • Najia Hajjaj-Hassouni
    • Bonnie Vlahos

    Original Research Open access 02 August 2018 Pages: 437 - 445

    

11. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

    • Alan J. Kivitz
    • Ulf Wagner
    • Brian Porter

    Original Research Open access 18 August 2018 Pages: 447 - 462

    

12. Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database

    • Jessica A. Walsh
    • Xue Song
    • Yujin Park

    Original Research Open access 18 August 2018 Pages: 463 - 474

    

13. Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs

    • Neil Bodick
    • Toni Williamson
    • Ruth Lightfoot-Dunn

    Original Research Open access 10 September 2018 Pages: 475 - 498

    

14. Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjögren’s Syndrome

    • Masako Tsukamoto
    • Katsuya Suzuki
    • Tsutomu Takeuchi

    Original Research Open access 25 September 2018 Pages: 499 - 505

15. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis

    • Leslie R. Harrold
    • George W. Reed
    • Joel M. Kremer

    Original Research Open access 06 October 2018 Pages: 507 - 523

    

16. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

    • Ronald van Vollenhoven
    • Cameron Helt
    • David Muram

    Original Research Open access 24 October 2018 Pages: 525 - 536

    

17. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry

    • Philip J. Mease
    • Désirée van der Heijde
    • Jeffrey D. Greenberg

    Original Research Open access 23 October 2018 Pages: 537 - 550

    

18. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study

    • Boulos Haraoui
    • Shahin Jamal
    • Majed Khraishi

    Original Research Open access 28 October 2018 Pages: 551 - 565

    

19. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

    • Peter Nash
    • Laura C. Coates
    • William C. Ports

    Original Research Open access 09 November 2018 Pages: 567 - 582

    

20. Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases

    • Allan H. Morton
    • Tony Hosey
    • Brian LaMoreaux

    Case Series Open access 03 May 2018 Pages: 583 - 594

    

21. Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

    • Peter Nash
    • Iain B. McInnes
    • Steffen M. Jugl

    Correction Open access 01 June 2018 Pages: 595 - 595